Minimally invasive esophagectomy reduces morbidity

Share this article:

Patients with resectable esophageal cancer may reap more short-term benefits from minimally invasive esophagectomy, including fewer pulmonary infections, significantly shorter hospital stays, and better short-term quality of life, than do patients who have undergone traditional open surgery.

These findings come from the first randomized trial to compare the two methods, recently reported in The Lancet and involving 115 participants, aged 18 to 75 years, with resectable cancer of the esophagus or the gastroesophageal junction. Prof. Miguel A. Cuesta of the Department of Surgery at VU University Medical Centre, Amsterdam, Netherlands, and colleagues randomized patients from five study centers in the Netherlands, Spain, and Italy to open transthoracic esophagectomy or to minimally invasive transthoracic esophagectomy. The latter avoids thoracotomy and laparotomy. As the authors explain, surgical resection is regarded as the only curative option for resectable esophageal cancer, but pulmonary complications occurring in more than half of patients after open esophagectomy are of great concern.

In the first 2 weeks postoperatively, 16 of the 56 patients (29%) in the open esophagectomy group developed pulmonary infections, compared with five of the 59 patients (9%) undergoing minimally invasive surgery. In-hospital pulmonary infections developed in 19 (34%) of the open surgery patients, compared with seven (12%) of the minimally invasive patients.

The minimally invasive group also had significantly less blood loss and shorter hospital stays as well as significantly less pain and vocal-cord paralysis.

The investigators noted no compromise in the quality of the resected specimen and no significant difference in the number of lymph nodes retrieved, the number of reoperations, or the rate of postoperative mortality between the two groups. One patient in the open surgery group died in the hospital as a result of anastomotic leakage, and two in the minimally invasive group died in the hospital as a result of aspiration and mediastinitis after anastomotic leakage. 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.